Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against leaders Eli Lilly and Novo Nordisk, as recent results show solid progress. Strong liquidity position provides a reasonable cash runway through 2027, supporting R&D initiatives and upcoming key clinical data releases.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Ryan Deschner - Raymond James & Associates, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Michael Ulz - Morgan Stanley, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Biren Amin - Piper Sandler & Co., Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $32.07, representing a +1.39% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
